Dapagliflozin combination improved glycemic control, reduced body weight in type 2 diabetes
Stephan Matthaei, MD,of the Diabetes-Zentrum Quakenbrck in Germany, and colleagues evaluated participants (mean age, 61 years) with an HbA1c of 7% to 10.5% receiving sulfonylurea andmetforminwho were assigned to receivedapagliflozin(Farxiga, Bristol-Myers Squibb and AstraZeneca) 10 mg/day (n=109) or placebo (n=109) to determine the effect on inadequate glycemic control.
Compared with the placebo group, the dapagliflozin group had significantly reduced HbA1c levels from baseline to 24 weeks (P<.0001). At week 24, more patients on dapagliflozin achieved a therapeutic glycemic response compared with those receiving placebo (P<.0001). Fasting plasma glucose and body weight also decreased more throughout the study period among the dapagliflozin group compared with placebo (bothP<.0001).